-
Mashup Score: 0Emerging Nomogram May Predict Outcomes After PSMA PET-Guided Salvage Radiotherapy in Patients with Prostate Cancer - 11 month(s) ago
In a multinational, multicenter study of over 1,000 patients with recurrent prostate cancer, researchers developed and validated a nomogram that achieved a 72 percent concordance index for the prediction of biochemical recurrence after PSMA PET-guided salvage radiotherapy.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet
-
Mashup Score: 0FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging - 11 month(s) ago
Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
FDA Approves New #PSMA PET Agent POSLUMA for #ProstateCancer Imaging https://t.co/RsKSJX6Akn @ACRRFS @ACRYPS @SocietyAbdRad @SAR_AARC @RadiologyACR @RSNA @PennRadiology @BrighamRad @EmoryRadiology @YaleRadiology @JeffersonRads @CooperRadRes @BlueEarthDx #radiology #RadRes https://t.co/Ie201qLEW4
-
-
Mashup Score: 0FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging - 11 month(s) ago
Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
FDA Approves New #PSMA PET Agent POSLUMA for #ProstateCancer Imaging https://t.co/izD3sbZSeI @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @SocietyAbdRad @PennRadiology @MontefioreRAD @NYUImaging @OSURadiology @UABRadiology @EmoryRadiology @BlueEarthDx #radiology #RadRes https://t.co/dUn9hm5X7z
-
-
Mashup Score: 0Emerging Nomogram May Predict Outcomes After PSMA PET-Guided Salvage Radiotherapy in Patients with Prostate Cancer - 11 month(s) ago
In a multinational, multicenter study of over 1,000 patients with recurrent prostate cancer, researchers developed and validated a nomogram that achieved a 72 percent concordance index for the prediction of biochemical recurrence after PSMA PET-guided salvage radiotherapy.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
Emerging Nomogram May Predict Outcomes After #PSMA PET-Guided Salvage #Radiotherapy for #ProstateCancer https://t.co/Xf6NT2LUHe @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @SocietyAbdRad @NYUImaging @PennRadiology @DukeRadiology @OchsnerRads @UVARadiology #radiology #RadRes https://t.co/R3so9j2Hsy
-
-
Mashup Score: 0FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging - 11 month(s) ago
Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
FDA Approves New #PSMA PET Agent POSLUMA for #ProstateCancer Imaging https://t.co/U4aeiVpqc8 @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @SocietyAbdRad @RadiologyUSC @StanfordRad @UofURadiology @UWRadiology @UCSFimaging @UTSW_Radiology @BlueEarthDx #radiology #RadRes https://t.co/EX6b3nONBp
-
-
Mashup Score: 0Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL - Full Text View - ClinicalTrials.gov - 11 month(s) ago
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
Dr Mohammad Atiq @DrMohammadAtiq1 @nciccr_gmb @thenci will present a Trials In Progress poster tomorrow at the #ASCO23 #ProstateCancer Poster session @ASCO 8-11am CDT Here is a link with more info on the trial: https://t.co/GXPPojV8LR #PSMA #PET #imaging https://t.co/UdjSThtBoG
-
-
Mashup Score: 0Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL - Full Text View - ClinicalTrials.gov - 11 month(s) ago
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL – Full Text View.
Source: clinicaltrials.govCategories: Hem/Oncs, Latest HeadlinesTweet-
@GlopesMd @ASCO For pts w/ #BCR or recurrent #ProstateCancer one option is this trial which recently opened @theNCI & involves serial #PSMA #PET imaging 👉🏽trial link: https://t.co/GXPPojV8LR @asco #ASCO23
-
What To Do w/+ PSMA PET & Neg Conventional Imaging? For pts w/ #BCR or recurrent #ProstateCancer one option is this trial which recently opened @theNCI & involves serial #PSMA #PET imaging 👉🏽trial link: https://t.co/GXPPojV8LR @asco #ASCO23 https://t.co/jbhgzAUujM
-
-
Mashup Score: 0FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging - 11 month(s) ago
Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
FDA Approves New #PSMA PET Agent POSLUMA for #ProstateCancer Imaging https://t.co/uv54GDbHFI @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @SNM_MI @SocietyAbdRad @SAR_AARC @PennRadiology @EmoryRadiology @NYUImaging @BURadiology @DukeRadiology @BlueEarthDx #radiology #RadRes https://t.co/qKAxAAegty
-
-
Mashup Score: 0FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging - 11 month(s) ago
Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
FDA Approves New #PSMA PET Agent POSLUMA for #ProstateCancer Imaging https://t.co/wWN5ZaxETS @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @RSNA @PennRadiology @EmoryRadiology @UABRadiology @MontefioreRAD @NYUImaging @BURadiology @BlueEarthDx @BrighamRad #radiology #RadRes https://t.co/NnFghYQZjp
-
-
Mashup Score: 0Emerging Nomogram May Predict Outcomes After PSMA PET-Guided Salvage Radiotherapy in Patients with Prostate Cancer - 11 month(s) ago
In a multinational, multicenter study of over 1,000 patients with recurrent prostate cancer, researchers developed and validated a nomogram that achieved a 72 percent concordance index for the prediction of biochemical recurrence after PSMA PET-guided salvage radiotherapy.
Source: Diagnostic ImagingCategories: Latest Headlines, RadiologyTweet-
New Nomogram May Predict Outcomes After #PSMA PET-Guided Salvage #Radiotherapy for #ProstateCancer https://t.co/n3e2klGNcW @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @SocietyAbdRad @RadiologyUcla @RadiologyUSC @StanfordRad @UTSW_Radiology @OHSURadiology #radiology #RadRes https://t.co/y23Vk1GRQH
-
New Nomogram May Predict Outcomes After #PSMA PET -Guided Salvage #Radiotherapy for #ProstateCancer https://t.co/yRZNGUwKWb @ACRRFS @ACRYPS @RadiologyACR @ARRS_Radiology @SocietyAbdRad @RadiologyUSC @StanfordRad @UTSW_Radiology @OHSURadiology @RadiologyUcla #radiology #RadRes https://t.co/VGCatiscmf